GI Colorectal / Rectal Cancer (CRC)

Localized

Colon

Anal (Squamous Cell)

Rectal

Adjuvant

Neoadjuvant / Adjuvant

Neoadjuvant / Adjuvant

Non-Intervention CRC

Metastatic Anal

1st Line

2nd Line

3rd Line

Beyond 3rd Line HER2+

HER2+

IRB# 21658
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

IRB# 22465
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

IRB# 19576
Phase I B Study to Assess the Safety of Neoadjuvant TAS-102 (Lonsurf) with Concurrent Radiation in Previously Untreated Rectable Stage II and Stage III Rectal Cancer

IRB# 20980
Immunotherapy during neoadjuvant therapy for rectal cancer, a phase II randomized multi-center trial with and without APX005M, an anti-CD40 agonist

IRB# 19296
A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer

IRB# 21926
A Phase 1a/b Dose Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

IRB# 20408
A Phase 1a/b Dose Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

IRB# 20408
A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

IRB# 20747
A Phase 3 Study to Evaluate the Efficacy and Safety of Olaparib Alone Or In Combination With Bevacizumab Compared To Bevacizumab With 5-Fu In Participants With Unresectable Or Metastatic Colorectal Cancer Who Have Not Progressed Following First-Line Induction Of FOLFOX With Bevacizumab

IRB# TBD
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients

IRB# EAY131
MATCH

IMMUNOTHERAPY
during neoadjuvant therapy for rectal cancer, a phase II randomized multi-center trial with and without APX005M, an anti-CD40 agonist

CROSS-DISEASE TRIALS:

IRB# 20075
[NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

IRB# 20747
A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

http://www.ohsu.edu/research/rda/so/knight.php

No Trials Currently Available

Key:

Open for Enrollment

In Development

Enrollment on Hold

2/2/2021